Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases by Rainer H Straub
Introduction
In 1916, the diabetologist Elliott P Joslin recognized that 
‘hyperglycemic situations appear after infectious diseases, 
painful conditions such as gall stones, and trauma’ [1]. In 
1920, Pemberton and Foster described impaired glucose 
regulation in soldiers with arthritis [2]. In 1924, 
Rabinowitch observed that diabetic patients need much 
more insulin during infection [3]. In 1929, Root sum-
marized the presence of an inadequately high need for 
insulin in diﬀ erent diseases, and he called the pheno-
menon ‘insulin resistance’ (IR) [4].
Over the last century, IR was found in physiological 
states, disease states, and diseases such as diabetes 
mellitus, obesity, infection, sepsis, arthritis of diﬀ erent 
types (including rheumatoid arthritis (RA)), systemic 
lupus erythematosus, ankylosing spondylitis, trauma, 
painful states such as postoperative pain and migraine, 
schizophrenia, major depression, and mental stress, to 
name the most important (chronology of events is 
summarized in Table 1). IR thus seems to be present in 
many diseases states outside the ﬁ eld of diabetology or – 
more speciﬁ cally  – exterior of inherited IR syndromes 
(called the type A syndrome of IR) and also beyond 
autoantibodies to insulin or insulin receptor (type B 
syndrome of IR) [5].
When considering these diseases and disease states, 
one observes two major clusters of clinical entities that 
are linked to IR: inﬂ ammation with an activated immune/
repair system; and increased mental activation. In this 
clearly deﬁ ning distinction, obesity and type  2 diabetes 
mellitus (T2D) can be integrated into the ﬁ rst cluster due 
the inﬂ ammatory aspect of IR in these entities [6-9]. 
However, obesity and consequently T2D might also be 
integrated into the latter cluster because chronic mental 
stress is a well-known forerunner of obesity in 
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Table 1. History of insulin resistance from diff erent perspectives of research in the fi elds of diabetology, infection/
infl ammation, pain, mental activation, trauma, and rheumatology
Year Author Phenomena Reference
1916 Joslin Hyperglycemia in infectious diseases,a painful gallstones,b traumac [1]
1920 Pemberton and Foster Impaired glucose regulation in soldiers with arthritisa [2]
1924 Rabinowitch Enormous doses of insulin needed in infected diabetic patientsa [3]
1929 Root IR in the context of diff erent diseasesa,b,c [4]
1936 Himsworth and Kerr Insulin-sensitive and insulin-insensitive diabetes [106]
1938 Thomsen Traumatic diabetesc [107]
1938 Warren β-cell defects in older longstanding diabetic patients In [108]
1950 Liefmann IR in rheumatoid arthritis (combined glucose and insulin test)a [16]
1956 Arendt and Pattee IR in obese subjects [109]
1957 Collins IR in schizophreniad [110]
1960 Yalow and Berson IR in diabetic subjects (high glucose despite high insulin) [24]
1963 Randle and colleagues Fatty acids support IR [25]
1965 van Praag and Leijnse Major depression induces IRd [111]
1965 Butterfi eld and Wichelow Forearm insulin sensitivity test [112]
1970 Shen and colleagues Quadruple insulin sensitivity test [113]
1979 DeFronzo and colleagues Euglycemic insulin clamp technique in combination with radioisotope turnover,  [114]
  limb catheterization, indirect calorimetry, and muscle biopsy
1979 Wolfe Review: sepsis and trauma induce IRa,b,c [115]
1982 Kasuga and colleagues Insulin induces tyrosine phosphorylation of the insulin receptor [116]
1982 Ciraldi and colleagues Reduced insulin-stimulated glucose uptake in type 2 diabetes [117]
1984 Grunberger and colleagues Dissociation between normal insulin binding and defective tyrosine kinase activity of  [118]
  the insulin receptor
1986 Garvey and colleagues Hyperinsulinemia induces insulin receptor desensitization [119]
1987 Svenson and colleagues IR in rheumatoid arthritisa [17]
1988 Krieger and Landsberg Hypertension, hyperinsulinemia, insulin resistance and SNS [120]
1988 DeFronzo Hyperglycemia decreases glucose transport and inhibits beta-cell function (glucotoxicity) [121]
1988 DeFronzo, Reaven Increased free fatty acids play key role in IR, β-cell dysfunction, and hepatic  [121,122]
  gluconeogenesis (lipotoxicity)
1988 Uchita and colleagues,  Pain infl uences IR via the HPA axis and SNSb [123,124]
 Greisen and colleagues
1992 Feingold and Grunfeld Cytokines like TNF play a role in hyperlipidemia and diabetesa [125]
1993 Hotamisligil and colleagues TNF critically infl uences IRa [34]
1994 Moberg and colleagues Mental stress induces acute IR in type 1 diabetic patientsd [126]
1996 Keltikangas and colleagues Mental stress is accompanied by IR in nondiabetic peopled [127]
1999 Björntrop IR as a consequence of exaggerated HPA axis and SNS activation (CNS stress is the trigger)d [28]
2000 Chrousos Mental stress-induced hypercortisolism induces IR (the pseudo-Cushing state)d [29]
2000 Seematter and colleagues Mental stress acutely increases insulin-stimulated glucose utilization in healthy lean  [128]
  humans but not in obese nondiabetic humansd
2004 Tso and colleagues Patients with systemic lupus erythematosus demonstrate IR independent of  [19]
  autoantibodies to insulin receptora
2005 Kiortsis and colleagues,  Patients with ankylosing spondylitis and rheumatoid arthritis have IR, which is [20,44]
 Stagakis and colleagues reduced after anti-TNF therapya
2007 Larsen and colleagues IL-1ra improved beta-cell secretory function in type 2 diabetic patients (no infl uence on IR)e [129]
2008 Fleischman and colleagues,  Salsalate improved insulin sensitivity in young obese adults and in type 2 diabetic patients [43,130]
 Goldfi ne and colleagues
2010 Schultz and colleagues Patients with rheumatoid arthritis show IR, which can be reduced by blocking IL-6a [45]
2012,  DIAGRAM and colleagues,  Human gene polymorphisms link both infl ammation and metabolic disease [93,131]
2014 Fall and Ingelsson
CNS, central nervous system; DIAGRAM, DIAbetes Genetics Replication And Meta-analysis Consortium; HPA, hypothalamic–pituitary–adrenal; IL, interleukin; IR, 
insulin resistance; OGTT, oral glucose tolerance test; SNS, sympathetic nervous system; TNF, tumor necrosis factor. aInsulin resistance as a consequence of infection or 
infl ammation. bInsulin resistance as a consequence of pain. cInsulin resistance as a consequence of trauma. dInsulin resistance as a consequence of mental activation. 
eApproved by the US Food and Drug Administration for patients with type 2 diabetes mellitus.
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approximately 40% of investigated stressed subjects 
[10-15]. At this point the question is why these two 
disease clusters are linked to IR, which will be addressed 
in the present paper.
Since chronic inﬂ ammatory diseases (CIDs) such as 
arthritis were among the ﬁ rst to be linked to IR [2,16], 
newer work in rheumatology has recognized IR in many 
CIDs [17-20], cytokine-neutralizing strategies decrease 
IR in CIDs [20-22], and CID patients are at increased risk 
to develop T2D [23], the special view from rheumatology 
to IR is understandable and necessary. Th e reader will see 
that IR is not an endocrine disorder per se, but more a 
disorder of several systems, better tackled from an inter-
disciplinary standpoint of neuroendocrine immunology.
Features of insulin resistance and pathophysiology
Originally, IR was deﬁ ned as a subnormal biologic 
response to a certain insulin concentration, whereby the 
word subnormal already suggests illness. In the late 
1950s, Yalow and Berson developed the radio immuno-
assay to measure circulating insulin in the blood. In this 
early paper, they described a state of IR in T2D patients: 
‘… [there is a] lack of responsiveness of blood sugar, in 
the face of apparently adequate amounts of insulin 
secreted …’ [24]. Th e classical characteristics of IR are 
presented in Table  2. Elements given in this table work 
together to induce clinically observed hyperglycemia and 
very low density lipoprotein hyperlipidemia (trigly cer-
ides) despite elevated insulin levels.
IR is measured by diﬀ erent techniques, whereby the 
gold standard is the hyperinsulinemic euglycemic clamp 
and the silver standard is the frequently sampled 
intravenous glucose tolerance test (Table 3). To study IR 
or insulin sensitivity in CIDs, simple fasting indices are 
often used such as the homeostasis model assessment 
insulin resistance and the Quicki (Table  3), which are 
adequate when applied in larger clinical studies.
Pathophysiology of insulin resistance – a chronology of 
models
Th e ﬁ rst viable theory on IR was presented by Randle, 
who suggested that IR in muscle and adipose tissue is 
based on the glucose–fatty acid cycle [25]. Th e theory 
suggested that IR is a consequence of an increased 
presence of circulating fatty acids and ketone bodies that 
lead to defects in glucose utilization and an ever-
increasing insensitivity to insulin. Th e biochemical 
principles of this model are still valid and useful today.
Further clariﬁ cation throughout the 1960s and 1970s 
came from endocrine diseases that were accompanied 
by IR. Th e explanatory power of hormones is 
particularly obvious in diseases with an overproduction 
of a distinct glucogenic hormone such as in Cushing’s 
syndrome (cortisol), acromegaly (growth hormone), 
pheochromocytoma (catechol amines), glucagonoma, 
thyro tocicosis (thyroxine, triiodothyronine), and insulinoma 
(IR as a consequence of insulin receptor desensitization) 
[5]. Since these diseases were accompanied by IR, the res-
pective hormones became the focus of IR research (called 
the insulin antagonists; not to speak of antibodies to 
insulin or insulin receptor). However, in the diseases 
mentioned in Table 1, IR was not accompanied by 
enormous serum levels of hormones as in these endo-
crine tumors.
Physiological conditions and disease states with up-
regulated stress hormones were found to be accompanied 
by IR, such as in psychological stress, psychiatric disease, 
starvation, fasting, and others (Table 1). Th e activation of 
stress axes is very closely related to the abovementioned 
cluster of mental activation. For example, an overactive 
stress system has been described in diﬀ erent forms of IR 
[26,27]. Stress system activation is an explanatory model 
for IR, still in vogue [28-33], but in 1993 the mainstream 
of research turned to inﬂ ammation-related IR (discussed 
in the paragraphs following the next paragraph) [34].
In addition, several authors indicated the central role of 
the brain because it dictates nutrient intake and foraging 
behavior. Excess energy intake per se would be an 
important factor for obesity and, thus, a possible cause of 
subsequently developing IR. Th is has been demonstrated 
in humans to play a role in congenital severe obesity with 
congenital leptin deﬁ ciency [35], or a mutation in the 
melanocortin receptor type 4 [36]. Th ere is a highly 
delicate system of hypothalamic regulation of satiety 
Table 2. Classical signs of insulin resistance until 1995 
[5,28,121,122]
Structure, organ Observed change
Insulin receptor Inhibited
Insulin receptor signaling cascade Inhibited
Muscle
 Glycogen synthase Inhibited
 Hexokinase II Inhibited
 Pyruvate dehydrogenase Inhibited
Liver
 Hepatic glucose production  Stimulated
 (gluconeogenesis, glycogenolysis)
 Insulin clearance Stimulated
Adipose tissue
 Free fatty acid mobilization Stimulated




aTriglyceride–free fatty acid–very low density lipoprotein–triglyceride cycle. 
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versus food intake, which is inﬂ uenced by distinct path-
ways within the brain and from the periphery [31,37]. 
Close relationships exist with psychological components 
comprising mood disturbances, altered reward percep-
tion and motivation, or addictive behavior [38]. Th e 
interested reader is referred to comprehensive reviews of 
the subject [31,38,39].
Nowadays, inﬂ ammation-mediated IR is another im-
por tant explanatory platform of IR in adipocytes, myo-
cytes, and hepatocytes [7,34,40,41]. Disruption of insulin 
signaling at the level of insulin receptor substrate-1 and 
insulin receptor substrate-2 and further downstream by 
tumor necrosis factor (TNF) signaling, toll-like receptor 
signaling, nuclear factor-κB and inhibitor of nuclear 
factor-κB, and FoxO1 activation are key elements of 
inﬂ ammation-related IR [6,40,42]. Crucial cytokines in 
IR are TNF, interleukin (IL)-1β, IL-6, IL-18, and 
adipokines. Although the concept behind inﬂ ammation-
related IR is convincing, neutralization of TNF or IL-1β 
had no inﬂ uence on IR in obese patients or T2D patients 
[40]. Th is might depend on the redundancy of cytokine 
pathways because, typically, only one cytokine is 
neutralized while many cytokines act in parallel. Th is 
might be overcome by a broader inhibition of pro-
inﬂ ammatory signaling pathways, which has been shown 
for salsalate therapy that reduced IR in patients with T2D 
[43]. In patients with CIDs, TNF and IL-6 neutralizing 
strategies reduced IR [20,44,45]. Until now it is not clear 
why the neutralizing strategies perfectly improve insulin 
sensitivity in CIDs but not in patients without CIDs. Th is 
discrepancy will be discussed in a model of IR that 
integrates the ﬁ ndings of CID patients (see below).
In addition to the cytokine-centered theory of IR, a 
relatively new aspect is nutrient-induced inﬂ ammation 
that leads to endoplasmic reticulum stress, activation of 
jun-N-terminal kinase, and inhibition of insulin receptor 
substrate-1 and AKT (v-akt murine thymoma viral onco-
gene homolog  1) and, thus, IR in the liver and adipose 
tissue [6]. In this model of metaﬂ ammation (metabolic 
inﬂ ammation), free fatty acids can activate toll-like 
receptors, and free fatty acids and glucose undergoing 
oxidation in mitochondria stimulate free radical 
production, both of which inhibit insulin signaling [6,46].
Th e theory describes that nutrient overload in our 
modern society of aﬄ  uence gradually increases the 
involvement of immune system pathways. Th is leads to 
ongoing inﬂ ammation, mainly in fat tissue as 
substantiated by leukocyte inﬁ ltration (the macrophage is 
the big player). In consequence, involvement of these 
inﬂ ammatory pathways intensiﬁ es the inhibition of 
metabolic pathways [6]. In addition, in patients with 
obesity, changes of the gut microbiota were observed, 
which in itself can be an inﬂ ammatory factor that 
contributes to IR [47-49].
Table 3. Methods to measure insulin resistance
Technique Notes Reference
Reference methods
 Hyperinsulinemic euglycemic clamp Gold standard, highly invasive [114]
 Frequently sampled intravenous glucose tolerance test Silver standard, invasive [132]
Oral glucose tolerance test
 Insulin sensitivity glycemic index = 1 + 2 /(INSp × GLYp) Most commonly used, little invasive [133]
 Whole body insulin sensitivity Little invasive [133]
 Muscle IS = (Δglucose / Δtime) / mean plasma insulina Little invasive [134]
 Hepatic IS = glucose0–30 minutes[AUC] × insulin0–30 minutes[AUC]
b Little invasive [134]
Fasting simple indices
 Homeostasis model assessment insulin resistance (HOMA-IR) Non-invasive [133]
 Newer version of the HOMA-IR (HOMA2-S) Non-invasive [133]
 FGIR = fasting glucose (mg/dl) / fasting insulin (mU/l) Non-invasive [133]
 Quicki = 1 / (log fasting insulin (mU/l) + log fasting glucose (mg/dl)) Non-invasive [133]
Biochemical markers of insulin resistance
 Sex hormone binding globulin Non-invasive [133]
 Insulin-like growth factor binding protein 1 Non-invasive [133]
 Other markers: YKL-40, alpha-hydroxybutyrate, soluble CD36, leptin,  Non-invasive [135]
 resistin, interleukin-18, retinol binding protein-4, and chemerin
AUC, area under the curve; GLYp, area under glucose curve; INSp, area under the insulin curve; IS, insulin sensitivity. aThe rate of decay of plasma glucose concentration 
from its peak value to its nadir (Δglucose / Δtime) during the oral glucose tolerance test. bThe product of the total AUC for glucose and insulin during the fi rst 30 
minutes of the oral glucose tolerance test.
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In this short pathophysiology collection of IR, we 
recog nize again the two clusters linked to IR: inﬂ am-
mation with an activated immune/repair system; and 
increased mental activation (mood, food intake, stress 
and stress axes). However, the appearance of the two 
clusters is not yet explained by the interplay of the 
abovementioned pathophysiological elements. Possibly, 
published theories on IR with an evolutionary perspective 
might help to explain the two clusters.
Evolutionary medicine – theories of insulin 
resistance, 1962 to 2014
Th e theories of IR are summarized in Table  4 and are 
shortly recapitulated here. Th e thrifty genotype hypo the-
sis of 1962 states that a gene has been positively selected 
for an exceptionally eﬃ  cient intake and utilization of 
food, which was good for hunter-gatherers in a feast/
famine environment but is not good for modern people 
in a world of plenty. In the original theory, a single gene 
was made responsible for rapid postprandial insulin 
release that supported quick storage of energy-rich 
substrates (called the quick insulin trigger) [50,51]. While 
the original theory focused on the quick insulin trigger, 
an alternative model focused on possible genes involved 
in IR [52]. Today, we know that obesity and IR are based 
on a polygenic background with many single nucleotide 
polymorphisms with small eﬀ ect sizes. Selection on such 
mutations would probably be very weak because the 
individual advantages they would confer would be very 
small. Th e theory has been criticized due to modest 
support by genetic analyses; it has been even rejected, 
but it is still in use and has been adapted by researchers 
in the ﬁ eld of eating disorders [53].
Another theory of starvation-induced IR proposes that 
IR of the muscle during fasting is a positively selected 
program to maintain high circulating glucose levels in 
order to protect muscle from proteolysis during star-
vation [52,54]. In addition, during starvation, lipolysis is 
switched on, leading to provision of free fatty acids and 
then ketone bodies that can be used by the brain. Both 
mechanisms spare glucose and glucogenic amino acids in 
the muscle. IR in the context of starvation is of a special 
form because insulin levels are very low, no inﬂ ammation 
accompanies starvation, and counterregulatory hor-
mones such as glucagon and cortisol are continuously 
upregulated. Th is situation does not apply to IR observed 
in CIDs and obesity because hyperinsulinemia and 
inﬂ ammation are a hallmark.
Another important theory of IR is the thrifty phenotype 
hypothesis [55,56]. Th is model is based on the important 
observations that underweight babies more often develop 
IR and obesity compared with normal weight children. In 
this theory, intrauterine malnutrition and other fetal 
constraints induce insulin deﬁ ciency (lack of the 
growth-promoting activities of insulin) and a postnatal 
state of regulatory IR, which leads to rapid postnatal 
increase of adipose tissue that remains stable throughout 
life (accompanied by cardiovascular disease in the older 
person, and so forth) [57]. In many studies all over the 
world, the epidemio logical ﬁ ndings were very supportive 
of the model [55]. Th e theory proposes that environ-
mental factors are the dominant cause of obesity, and 
that epigenetic intrauterine programming plays the 
critical role [58,59]. Th is theory has been reﬁ ned in the 
predictive adaptive response model. In this supplement 
to the original theory, the relative diﬀ erence in nutrition 
between prenatal and postnatal environment, rather than 
an absolute level of nutrition, determines the risk of IR 
[60]. Both thrifty phenotype theories are accepted in IR 
research because they have been conﬁ rmed in many 
studies in humans and animals. Th ese days, it is amazing 
that a nongenetic theory has received so much support 
and attention.
Based on the thrifty genotype hypothesis, IR and 
immune activation were recognized as an adaptive 
positively selected program to combat infections (the 
ﬁ ght infections theory of IR). Th e activation of the 
immune system during infectious disease and inﬂ am-
mation induces IR, which leads to redirection of glucose 
to the activated immune system [61]. In a modern form, 
this was integrated into the concept of immune cell 
activation by pathogen-sensing and nutrient-sensing 
pathways (with cytokines, toll-like receptors, jun-N-
terminal kinase, and so forth) [62]. Here, even nutrients 
can induce an inﬂ am matory state that can support IR, 
which is probably a dilemma after exaggerated food 
intake when nutrients cannot be adequately stored in fat 
tissue and elsewhere (nutrient overﬂ ow problem).
Similarly based on the thrifty genotype theory is the 
breakdown of robustness theory, which states that a 
robust glucose control system developed during evolu-
tion. Th e breakdown of this robust glucose control 
system induces positive disease-stabilizing feedback 
loops leading to IR. Th e critical determinant of the 
breakdown is TNF [63]. Th is theory incorporates many 
accepted aspects but TNF is not the sole patho physio-
logical factor.
With the discovery of leptin, a negative feedback loop 
between adipose tissue and food intake was discovered. 
While in earlier times many argued that energy 
homeostasis operates primarily to defend against weight 
loss, the discovery of the leptin negative feedback loop 
speaks for homeostatic mechanisms that inhibit un-
controlled weight gain. Th e central resistance model 
states that central hypothalamic pathways are defective 
(resistant to leptin and others such as insulin). Th is leads 
to increased food intake and the resulting obesity induces 
IR [64]. Th is theory has much value because it added the 
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central regulation of food intake to the peripheral 
pathophysiologic pathways.
Finally, the good calories–bad calories theory explains 
that our present food is markedly diﬀ erent from paleo-
lithic food. Particularly, high energy-dense carbohydrates 
are consumed too often, which induces inadequate 
hyperinsulinemia [65]. Long-term hyperinsulinemia is 
the platform for obesity and disease sequelae. Others 
hypothesized that disparities between paleolithic and 
contemporary food might be important factors under-
lying the etiology of common western diseases [66]. 
Typically the type of ingested lipids and the relative 
amount of carbohydrates/lipids versus proteins is a 
problem.
In conclusion, the theories already indicate that IR can be 
an important aspect to support the brain and the activated 
immune system. As such, IR can be seen as a positively 
selected program to support the brain or immune system. 
In the following sections, this concept is further developed 
by including aspects of energy regulation.
Energetic benefi ts of insulin resistance for 
non-insulin-dependent tissue
At this point, I recapitulate that IR increases circulating 
glucose and free fatty acids that are not taken up in 
adipose tissue, liver, and muscle, and are now freely 
available to all non-insulin-dependent tissues. Th e two 
main proﬁ teers of hyperglycemia are the central nervous 
system and the immune system because either glucose, 
free fatty acids (not the brain), or ketone bodies are 
energetic substrates. Both of these organs do not become 
insulin resistant. In contrast, the immune system proﬁ ts 
from insulin because it is an important growth factor for 
leukocytes and, with the help of insulin, major glucose 
transporters like glucose transporter-3 and glucose 
transporter-4 are upregulated on all leukocyte sub popu-
lations [67]. In answering the question of whether, for 
example, hepatic glucose production really provides 
higher levels of circulating energy, the following simple 
calculations are presented for glucose (similar calcula-
tions can be done for free fatty acids).
One important factor of IR is overproduction of 
hepatic glucose [68]. In normal subjects, hepatic glucose 
production after an overnight fast is approximately 
2.0 mg/kg per minute. Under a situation involving IR, for 
example in T2D patients, insulin is 2.5-fold increased and 
the rate of fasting glucose production can increase to 
2.5 mg/kg/minute [68]. After an overnight fast during an 
observation period of 12  hours, the liver of a normal 
person of 80  kg bodyweight produces 115  g glucose. 
Using the above given numbers, a person with IR 
produces 144 g glucose, leading to an increase of 29 g in 
12  hours. An increase of 2  ×  29  g  = 58  g glucose in 
24  hours corresponds to 974  kJ in 24  hours, which is a 
pretty high number in the light of the normal metabolic 
rate of 10,000 kJ/day of an 80 kg person (sedentary way of 
life). Indeed, 974 kJ represents approximately 39% of the 
total energy need of the normally active central nervous 
system, or it represents 61% of the energy requirements 
of all resting immune cells (Table 5). IR is thus a perfect 
Table 4. Characteristics of theories on insulin resistance as observed from an evolutionary medicine standpoint
Theory of insulin resistance Year Reference
Thrifty genotype hypothesis: quick hyperinsulinemia after food intake to store energy in fat tissue and elsewhere  1962, 1999 [50,51]
(quick insulin trigger)
(Not so) Thrifty genotype hypothesis: starvation induces a special form of IR in order to conserve nitrogen  1979 [54]
(= amino acids from muscle and elsewhere)a
Thrifty phenotype hypothesis: intrauterine constraints induces IR and insulin defi ciency, which allows the organism to survive  1992, 2001 [55,56]
long enough to reproduce in a nutritionally deprived environment but which leads to obesity in a world of plenty; maternal 
constraints support IR (small mother, fi rst baby, many babies in parallel, maternal undernutrition, and similar)
Based on the thrifty genotype hypothesis: an insulin resistance genotype and a cytokine genotype exist (much IR, high  1999 [61]
cytokine response); IR is helpful for infections
Refi ned thrifty phenotype theory: predictive adaptive response model: the relative diff erence in nutrition between the prenatal  2004 [60]
and postnatal environment, rather than an absolute level of nutrition, determines the risk of IR
Central resistance model: there exists a homeostatic regulation of weight gain versus weight loss but defects in the weight  2004 [64]
loss system leads to obesity (for example, insulin and leptin signaling, SOCS3, PTB-1B)
Thrifty genotype plus breakdown of robustness: the basis is the thrifty genotype model; a robust glucose control system  2004 [63]
evolved during evolution, the breakdown of which induces positive disease-stabilizing feedback loops (TNF)
Thrifty genotype: integration of cellular pathogen-sensing and nutrient-sensing pathways (cytokines, TLRs, JNK, Ikkβ, PKC, ER stress) 2006 [62]
Good calories–bad calories hypothesis: wrong nutrients, particularly carbohydrates, lead to obesity and IR; a paleolithic diet  2010, 2012 [65,66]
has quite diff erent qualities that prevents obesity and western diseases
ER, endoplasmic reticulum; Ikkβ, inhibitor of nuclear factor-κB kinase β; IR, insulin resistance; JNK, jun-N-terminal kinase; PKC, protein kinase C; PTB-1B, protein tyrosine 
phosphatase 1B; SOCS3, suppressor of cytokine signaling 3; TLR, toll-like receptor; TNF, tumor necrosis factor. aThis is a special form of IR without hyperinsulinemia 
on the basis of a strong response of counterregulatory hormones. It is questionable to call it IR because of missing hyperinsulinemia and missing infl ammation. In 
addition, activity of the sympathetic nervous system is low while activity of the hypothalamic–pituitary–adrenal axis is high in the typical nadir.
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way to support the activity of the central nervous system, 
the immune system, and/or other insulin-independent 
tissues (for example, the heart; Table 5).
In conclusion, while IR is most often regarded as a 
pathological state to be treated, these numbers and the 
fact that IR is linked to so many diseases and disease 
states are indicative of a beneﬁ cial role of IR. While the 
value of IR can be estimated from the abovementioned 
numbers, the generation of the two disease clusters is not 
yet clear.
The selfi sh brain and the selfi sh immune system 
independently demand energy
Th is section demonstrates aspects of hypothetical 
character, and the reader is advised to critically judge the 
theoretical model. Th e basal metabolic rate of the entire 
body is determined when the following conditions are 
met [69]: awake, lying, after overnight fast, thermoneutral 
(no heat production due to low/high temperature), and 
no emotional stress [69]. Under these conditions, a 
person weighing 80  kg and 1.80  m in height needs 
approximately 10,000 kJ/day (Table 5).
Th e so-called minimal metabolic rate is lower than the 
basal metabolic rate because 15% of energy is spared 
during sleep, so that a 24-hour sleeping person weighing 
80  kg and 1.80  m in height needs 8,500  kJ/day. Th is 
amount of energy is not up for negotiation between the 
diﬀ erent organs. Th e delta value between this last 
number and the maximum of daily energy uptake in the 
gut (20,000 kJ/day; see Table 5) is 11,500 kJ/day. In this 
example, 11,500  kJ/day is the controllable amount of 
energy (CAEN) because allocation of the CAEN to 
diﬀ erent organs is controlled by the interplay of these 
organs. Th is amount of energy is available for negotiation. 
Th e question is which organs are dominant in regulating 
the CAEN. Dominance can be judged when looking at 
Table 5, which shows the main users of energy, but can 
also be derived from simple theoretical considerations.
For example, if a paleolithic hunter experiences tissue 
trauma with infection, the immune/repair system 
becomes strongly activated. In this life-threatening 
situation, regulation of CAEN allocation to the immune/
repair system must be independent of other organs and 
immediate (hierarchically, the highest level of control to 
survive). In this situation, circulating cytokines and 
activated sensory nerve ﬁ bers are responsible for the 
immediate reallocation of the CAEN to the activated 
immune system that increases energy consumption 
(Table  5) [70]. Th is reaction is called the energy appeal 
reaction [70].
Similarly, if the brain is active during hard forest work 
over 6  hours, for example, then the skeletal muscles, 
heart, lungs/diaphragm, and liver are also active, but 
most other organs are at minimal metabolic levels. Th is is 
particularly true for the gastrointestinal tract and the 
immune system. In this example of 6-hour forest work, a 
person weighing 80 kg and 1.80 m in height would need 
18,500  kJ for the entire day (calculated using data from 
[71]). Th e brain controls the additional CAEN of 
10,000 kJ when there is need for forest work. Likewise, if 
a paleolithic hunter needs to escape from a severe 
dangerous threat, the brain must control the CAEN. In 
such a life-threatening situation, the control of the CAEN 
by the brain must be independent of other organs (again, 
the highest level of control to survive).
With trauma/infection or ﬁ ght/ﬂ ight response, the 
activity of most organs depends on either the immune/
repair system or the central nervous system, respectively. 
We recently delineated that allocation of CAEN to the 
brain and muscles happens mainly during daytime, while 
allocation of CAEN to the immune/repair systems 
happens at night [70]. Th is circadian allocation of energy-
rich substrates is another clear indication of tight energy 
regulation. From these theoretical considerations, it 
becomes clear that either the immune/repair system or 
the central nervous system is a dominant regulator of the 
CAEN.
Coming back to the Introduction, with this model the 
two clusters of clinical entities linked to IR become 
understandable in terms of energy regulation. One 
recognizes two independent organs – the selﬁ sh immune 
system, and the selﬁ sh brain [37,72]  – related to the 
abovementioned clusters of inﬂ ammation with an 
Table 5. Energy expenditure of systems and organs under 
sedentary conditions (approximately 10,000 kJ/day)a 
[69,70,136-139]
 Energy expenditure
System/organ per day (kJ/day)
Muscle at restb 2,500
Central nervous system (brain and spinal cord) 2,500
Immune system in a quiescent statec 1.600
Liverd (including immune cell activity) 1,600
Heartb 1,200
Gastrointestinal tract (including gut immune system,  620
without liver, kidney, spleen)d
Kidneys 600
Spleen (erythrocytes plus leukocytes; 90% anaerobic) 480
Lungsd (including lung immune system) 400
Skind (including skin immune system) 100
a10,000 kJ = 2,388 kcal. bActivated muscle has a much higher metabolic rate: 
for example, a Tour de France bicyclist needs approximately 30,000 kJ/day, 
which is 20,000 kJ more than under sedentary conditions. The 20,000 kJ are 
used predominantly by the muscles and also the heart. At the upper limit of 
gastrointestinal resorption, the total body daily uptake (absorptive capacity in 
the gut) is 20,000 kJ/day. cModerate activation of the immune system increases 
daily energy needs to approximately 2,100 kJ/day, and strong activation 
increases the daily need to 3,000 kJ/day. dEnergy need is diffi  cult to estimate 
independent of the immune system in some organs.
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activated immune/repair system and of increased mental 
activation.
With the chronic inﬂ ammatory and chronic mental 
diseases that induce IR (listed in Table  1), the question 
arises of whether or not brain-supporting and immune 
system-supporting IR has been positively selected for 
acute disease or chronic disease. Such a distinction is not 
included in the available theories of IR, but it might be 
helpful to understand the role of IR in general.
A diff erence between acute and chronic disease
While an acute response is often adaptive and physio-
logical to correct alterations of homeostasis, a chronic 
disease process is often accompanied by the wrong 
program [70,73]. Looking at simple readout parameters, 
this can be demonstrated for immune/repair system 
activation and mental activation.
Th e acute activation of the immune/repair system is 
outstandingly important to ﬁ ght acute infections and 
trauma. However, longstanding inﬂ ammation in CIDs 
leads to severe disease sequelae as summarized recently 
[70,73]. Th e following disease sequelae are directly linked 
to CIDs: sickness behavior, anorexia, malnutrition, 
muscle wasting–cachexia, cachectic obesity, IR with 
hyper insulinemia, dyslipidemia, increase of adipose 
tissue near inﬂ amed tissue, alterations of steroid hor-
mone axes, elevated sympathetic tone and local 
sympathetic nerve ﬁ ber loss, decreased parasympathetic 
tone, hypertension, inﬂ ammation-related anemia, and 
osteopenia [70,73]. It was suggested that these sequelae 
of CIDs are a consequence of a high energy demand of 
the activated immune/repair system accompanied by 
water retention [70,73]. Acute activation of the immune/
repair system can be very helpful, but chronic activation 
is a harmful process that worsens the situation in an 
aﬀ ected patient.
Considering mental activation, we can also separate 
acute versus chronic. In the acute situation of emergency 
for a loved one, family members and hospital staﬀ  show 
strong mental activation that can lead to a higher state of 
activity, a better readiness to take action, but also poor 
sleep and symptoms of anxiety [74,75]. Similarly, 
student’s examination stress can lead to a higher state of 
activity but also to poor sleep and acute increase in 
anxiety scores [76,77]. Acute examination stress 
increased intake of highly palatable food in an un-
proportional manner [78]. In these acute situations, 
mental activation, poor sleep, and increase in food intake 
are important to overcome the challenging situation.
However, long-term caregivers of, for example, 
Alzheimer disease patients are more often obese than 
noncaregivers, demonstrate alterations typical of the 
metabolic syndrome, show a higher risk to develop major 
depression, and have a long-term increase in 
proinﬂ am matory markers [79-84]. Similarly, chronically 
stressed students in a highly competitive university 
environment showed an increased risk of obesity [14]. A 
dose–response relationship was found between chronic 
work stress and risk of general and central obesity that 
was largely independent of covariates such as age, sex, 
and social position [11], supported in other large studies 
[12,13]. Moreover, chronic job stress was related to an 
increased risk of the metabolic syndrome and even T2D 
[85-87]. Chronically poor sleep is related to metabolic 
risk factors, obesity, and inﬂ ammation [88].
Th is small collection demonstrates that activation of 
the immune/repair and central nervous systems are 
successful in acute emergency, but dangerous when 
applied chronically, leading to typical signs of obesity, 
metabolic derangement with IR, chronic inﬂ ammation, 
and increased risk for cardio vascular events [89]. Th e 
question is why there is such a clear distinction between 
acute and chronic, which determines the full picture of 
the metabolic syndrome and IR.
Evolutionary medicine – acute physiological 
response versus chronic disease
Earlier, it was demonstrated that a highly activated 
immune/repair system cannot be switched on for a long 
time because this would be very energy consuming [73]. 
A highly activated immune system is accompanied by 
sickness behavior and anorexia, which prevents adequate 
food intake and necessitates life on stored reserves 
(inﬂ ammation-induced anorexia). Under systemic in-
ﬂ am matory conditions, breaking down all reserves takes 
19 to 43  days [73]. A highly activated immune/repair 
system can need huge amounts of energy, which is 
exempliﬁ ed in the case of extensive burn wounds (up to 
20,000  kJ/day) [73]. Although this aspect demonstrates 
the extreme of the spectrum, it indicates that energy 
consumption is a critical factor during evolution.
I hypothesize that energy consumption and energy 
protection are the most critical determinants in 
evolution, to undergo either negative selection or positive 
selection, respectively. If alterations of homeostasis lead 
to marked energy consumption, the situation cannot be 
chronic – it must be acute. Since the total consumption 
time ranges between 19 and 43  days [73], an acute 
energy-consuming change of homeostasis must be 
started and terminated in this time frame. A very good 
example for this time window is the germinal center 
reaction of B-lymphocyte expansion and contraction that 
happens within approximately 21 to 28  days [90]. Most 
acute disease states are terminated within this time 
frame, such as infectious diseases, wound healing, and 
repair, but also strong mental activation in stressful 
situations must be termi nated because they are energy 
consuming, exempliﬁ ed in short-term stress [78]. During 
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evolution, respective homeostatic networks were 
positively selected for short-lived, acute, energy-
consuming responses but not for longstanding polygenic 
CIDs or chronic mental illness. Th ese chronic situations 
generated a huge negative selection pressure.
In contrast, if mutations were helpful to protect energy 
reserves, they were posi tively selected during evolution. 
Th is is true for memory responses because immediate 
reaction of an educated system can spare energy reserves. 
Th is is exempliﬁ ed by the immune memory that leads to 
shorter, more eﬀ ective and, ﬁ nally, less energy-consuming 
reactions towards microbes. Importantly, acquisition of 
immune memory during the primary contact must ﬁ t 
into the above speciﬁ ed time frame of 19 to 43 days (and 
this happens as exempliﬁ ed by the germinal center 
reaction in secondary lymphoid organs). In this context, 
tolerance versus harmless foreign antigens of microbes 
on body surfaces (see gut, skin, respiratory tract, 
urogenital tract) or harmless autoantigens is a memory 
function that spares energy reserves. Sometimes 
microbes such as Mycobacterium tuberculosis, Myco-
bacterium leprae, and viruses enable or mimic tolerant 
immune responses leading to longstanding infection, but 
ﬁ nally leading to death due to emaciation.
Similarly, neuronal memory can largely decrease time 
to accomplish successful foraging in the wild [91]. 
Neuronal memory systems are tuned to ancestral 
priorities in the context of foraging and other paleolithic 
tasks [92]. Additionally, tool-making, invention of 
language and writing, and storage of data on computer 
hard disks protects time and thus energy.
Another example of positively selected gene variants is 
observed for food ingestion and fat storage (not IR!), both 
of which are important in determining the above-
mentioned consumption time. Indeed, female Australo-
pithecus afarensis had a consumption time of approxi-
mately 19 days, while modern female Homo sapiens can 
rely on 43 days [73]. Particularly, fat storage has markedly 
increased over the last 3 to 4  million years of human 
evolution. Not surprisingly, the latest metaanalysis of 
genome-wide association studies of obesity and the 
metabolic syndrome (not IR) found polymorphisms in 
genes relevant for food intake such as FTO (fat mass and 
obesity related), MC4R (melanocortin receptor type  4), 
POMC (proopiomelanocortin, the precursor of melano-
cortin), and genes relevant for fat storage such as the 
insulin-stimulating GIPR (gastric inhibitory polypeptide 
receptor) [93].
Another important indication for positive selection of 
fat storage networks (not IR) is given by the fact that the 
number of adipocytes in humans is determined before 
puberty [57]. After puberty, the number of adipocytes 
stays constant with an annual exchange rate of 10% [57]. 
If spontaneous mutations lead to a phenomenon relevant 
before reproduction time, it will be easily transferred to 
oﬀ spring when it is an advantageous trait. Since the 
phenomenon still exists in modern children [57], we 
expect that fat storage was an important factor during 
evolution. Similarly, humans can deposit large amounts 
of fat in utero and are consequently one of the fattest 
species at birth [94]. In addition, newborn humans 
devote roughly 70% of growth expenditure to fat 
deposition during early postnatal months, which reduces 
the risk of energy stress during infections [94]. If the 
newborns are not able to store large amounts of fat tissue 
in utero, or if malnutrition is a problem in fetal life 
(thrifty phenotype model, see above; Table 4), a postnatal 
program seems to be switched on that supports obesity 
during childhood and adolescence [55,56]. Again this is 
an indication that important positively selected gene 
variants exist that serve storage of energy.
In conclusion, networks are positively selected if they 
serve acute, highly energy-consuming situations, which 
are terminated within 3 to 6 weeks. We perceive a 
chronic disease when it lasts for longer than 6 weeks, as 
used in classiﬁ cation criteria in RA and juvenile idio-
pathic arthritis [95]. In addition, gene variants are 
positively selected if they protect energy stores, which is 
relevant during the entire life (beyond weeks 3 to 6). 
Networks that lead to IR serve the acute activation of the 
selﬁ sh immune system or the selﬁ sh brain, but do not 
belong to networks that protect energy stores (Figure 1). 
In contrast, IR leads to loss of energy-rich substrates 
because it is a catabolic process (energy-rich fuels are 
consumed by non-insulin-dependent organs or are 
simply excreted) (Figure 1). If the hypothesis of the acute 
IR program is correct, then chronic IR in chronic 
inﬂ ammation, in CIDs, and in chronic mental activation 
or mental disease is a misguided acute program. In 
contrast to IR, food intake and storage of energy-rich 
substrates in adipose tissue per se is not a misguided 
program. In other words, obesity is not dangerous and 
obesity is not a disease [96]. Yet obesity becomes a 
problem if additional factors are switched on that usually 
serve acute energy-consuming situations (mental 
activation or inﬂ ammation). Per Björntorp once noticed 
that ‘some disease-generating factors, in addition to the 
basic condition of central obesity, is required for 
associated diseases to become manifest’ [96].
The new model of insulin resistance
With all this information, one can generate a new model 
of IR that builds upon the existing theories. Th e new 
model includes four new aspects: it respects much more 
the immune/repair system, whose energy requirements 
are enormous (Table  5) [70]; it juxtaposes the selﬁ sh 
brain and the selﬁ sh immune system on a similar hier-
archical level in terms of energy demand and 
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requirements (Table  5); it respects that energy require-
ments convey an evolutionary pressure (highly energy-
consuming states are acute (negative selection pressure), 
energy storage is beneﬁ cial (positive selection pressure)); 
and it accepts that either immune system activation or 
mental activation are equally important in inducing IR. 
On the basis of these elements, a new model of IR is 
presented in Figure  1. Th is model states that IR is an 
acute catabolic program to serve the selﬁ sh immune 
system or the selﬁ sh brain, positively selected for 
inﬂ ammation with an activated immune/repair system 
and for increased mental activation.
Several testable hypotheses can be generated from the 
new model, as follows. Obesity is only a problem if acute 
energy-consuming programs are switched on (either 
inﬂ ammation or mental activation cause the problem). 
Immunological tolerance should support the storage 
function of fat tissue and muscle. Nutrient-induced 
inﬂ ammation is only a problem if energy-rich fuels are 
not properly stored (there is an individual storage 
threshold). Intrauterine constraints (elements of the 
thrifty phenotype model) should set the thresholds for 
acute activation programs. While there is a clear link 
between fat tissue and brain (leptin), there should be 
similar pathways between the liver/brain and the muscle/
brain that regulate food intake – concerning the muscle/
brain pair, a recent paper found important links through 
muscle-derived IL-6 [97]. In CIDs, the selﬁ shness of the 
immune system should lead to an inhibition of brain-
dependent regulation of energy allocation. Likewise, in 
mental illness or chronic psychological stress, the 
selﬁ shness of the brain should lead to inhibition of the 
immune system-dependent regulation of energy allo-
cation. In CIDs and mental illness/stress, the two systems 
must inhibit each other.
The drivers of insulin resistance in chronic 
infl ammatory and mental diseases
A seminal study demonstrated the interrelation between 
the dose of subcutaneously injected recombinant human 
IL-6, serum levels of IL-6, and the increase of energy 
expenditure in healthy volunteers [98]. Injection of 0.1 μg 
recombinant human IL-6/kg bodyweight increased 
serum levels of IL-6 to approximately 10 to 15  pg/ml, 
1.0 μg led to 45 pg/ml, 3.0 μg stimulated a serum level of 
250 pg/ml, and 10 μg recombinant human IL-6/kg body-
weight was accompanied by an IL-6 serum concentration 
of more than 1,000  pg/ml. In parallel, the maximal 
increase of metabolic rate in percent of basal metabolic 
rate was 4%, 7.5%, 18%, and 25%, respectively [98]. Th is 
means that a visible inﬂ uence on energy regulation was 
observed at a serum level of 10 to 15 pg/ml, but the eﬀ ect 
was small in these healthy volunteers. In contrast, serum 
levels of 45 pg/ml were related to an increase in metabolic 
rate of 7.5%, which would amount to approximately 
750  kJ/day in a normal-sized healthy subject (basal 
metabolic rate: 10,000 kJ/day). An increase of serum IL-6 
from 1 to 2 pg/ml, as in healthy subjects [99], to 45 pg/ml 
thus induces a marked energy expenditure program.
Under consideration of the new model in Figure 1, we 
immediately recognize the problem of continuous 
inﬂ ammation in CIDs. CIDs such as RA are accompanied 
by markedly elevated serum levels of IL-6 ranging from 
40.0  pg/ml before anti-TNF therapy to 8.0  pg/ml after 
anti-TNF therapy [100]. Th e levels are thus much higher 
as compared with healthy subjects (1 to 2  pg/ml [99]). 
Untreated patients with RA should increase daily energy 
expenditure by 750  kJ/day (basal metabolic rate: 
10,000  kJ/day). Th is value of 750  kJ/day is remarkably 
similar to the number of 974 kJ/day obtained by hepatic IR 
as calculated above. Since we expect that several cytokines 
like TNF, IL-6, interferon gamma, interferon alpha, and 
others can drive a similar energy reallocation program, 
elevation of systemic cytokines explains why patients with 
CIDs do not need any other factor to provoke IR. Th ese 
CID patients do not need the activation of the brain and 
thus activation of stress axes to induce IR. Th e brain is 
silenced in CIDs (sickness behavior). IR can be stimulated 
by a direct inﬂ uence of cytokines on hepato cytes, adipo-
cytes, and myocytes. We now understand why cytokine-
neutralizing therapies work perfectly well in RA – because 
the key IR factor is removed. When cytokine-neutralizing 
strate gies do not work in obese or T2D people, other 
parallel factors must play an enormous role.
Th e inﬂ ammatory load is remarkably diﬀ erent in the 
situation of chronic mental illness or psychological stress 
where mild peripheral inﬂ ammation probably plays a 
small supportive role. When one compares serum levels 
of IL-6 as measured with the identical quantitative high-
sensitivity enzyme-linked immunosorbent assay tech-
nique, healthy subjects range between 1 and 2 pg/ml [99], 
caregivers show a mean value of 5.5  pg/ml [101], and 
subjects who report a high level of perceived hopelessness 
show 3.0  pg/ml [102]. Th ese levels correspond to mild 
activation of the immune system, but they would not lead 
to an energy reallocation program [98]. Th us, in mental 
activation, stress axes must play the major role for the 
observed IR (cortisol, adrenaline, growth hormone, 
glucagon). It is expected that neutralization of one cyto-
kine would not change IR in these mentally activated 
people. Furthermore, when cytokine neutralizing strate-
gies do not work in T2D patients, several factors in 
parallel are expected to drive IR. It is interesting that 
salsalate had a positive impact on IR in T2D [43], but this 
type of drug and other nonsteroidal anti-inﬂ ammatory 
drugs can also inhibit mental activation in various 
chronic psychiatric diseases [103-105], which is most 
probably related to reduced activation of stress axes.
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Figure 1. Pathophysiology of insulin resistance according to the new theory. Upper panel: Acute activation programs were positively 
selected for short-lived activation of either the brain or the immune system. Hierarchically, the brain and the immune system are on the same level. 
Activation of the brain mainly stimulates stress axes hormones and activates the sympathetic nervous system (SNS). This is supported by a mild 
infl ammatory process that is paralleled by mental activation (A). Activation of the immune system induces cytokines, chemokines, and danger 
signals. In addition, the infl ammatory process uncouples the locally infl amed area from the control of the brain by cytokine-induced hormone/
neurotransmitter production in the periphery independent of superordinate stress pathways. This leads to hepatic cortisol secretion [140], 
adrenocorticotropic hormone-independent cortisol secretion [141], and production of leukocyte hormones [142] and leukocyte neurotransmitters 
[143]. The activation of the immune system is accompanied by a mild stimulation of the hypothalamic–pituitary–adrenal axis (HPA) axis (albeit 
inadequately low in relation to infl ammation) and a somewhat stronger stimulation of the SNS (B). Despite activation of the SNS, anti-infl ammatory 
neurotransmitters of sympathetic nerve fi bers do not reach the uncoupled infl amed tissue [144]. Infl ammatory and mental activation are often 
accompanied by anorexia and sickness behavior, which aggravates energy shortage. Lower panel: Chronic energy storage and memory programs 
were positively selected. The major storage organs are fat tissue (glycerol, free fatty acids) and muscles (proteins). The liver is more a switchboard to 
interchange and renew energetic substrates. The main storage factor is insulin so that insulin resistance can be seen as a catabolic program induced 
by catabolic pathways (upper panel). Numbers in red give the typical time of energy provision by the respective organ (amino acids from muscle 
are spared from day 3 onwards). Storage is mainly supported by a positively selected program of foot intake/foraging behavior and memory. 
Memory is outstandingly important to spare energy-rich fuels (brain, immune system). Dashed black arrows in the lower panel demonstrate real 
and hypothetical connections between respective organs. Black numbers give a typical fi gure of stored energy in the respective organs. Dashed 
black line between upper and lower boxes separates the programs positively selected for acute (catabolic) versus chronic states (storage and 
memory). CAEN, controllable amount of energy (the energy that is regulated and negotiated between organs); 11βHSD1, 11-beta-hydroxy steroid 
dehydrogenase type 1 [140].
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Conclusions
IR is an unfavorable factor in CIDs because it supports 
the already activated immune system. IR is a direct 
consequence of the proinﬂ ammatory load. Th us, IR 
should be treated by neutralizing inﬂ ammatory cytokines 
or by inhibiting the immune system with disease-
modifying anti-rheumatic drugs in a more general way 
(like salsalate for T2D). Since IR is a very direct 
consequence of immune system activation, the primary 
goal is anti-inﬂ ammatory treatment. In CIDs, further 
treatment of IR beyond good inﬂ ammatory control is 
expected not to be needed. Since IR is a perfect diag-
nostic marker of an activated energy reallocation 
program (inﬂ ammation and mental activation), measur-
ing IR might be a suitable biomarker to study the control 
of systemic inﬂ ammation in CIDs. Since several 
cytokines induce IR in a redundant manner, IR might be 
a more integral systemic diagnostic marker than C-
reactive protein, the erythrocyte sedimentation rate, or 
single cytokines.
In addition to aspects of IR in CIDs, this review 
demonstrates an extended theory of IR that classiﬁ es IR 
as a beneﬁ cial positively selected program to support 
activation of the immune/repair system and the brain. IR 
makes sense in acute alterations of homeostasis in the 
context of short-lived diseases but is a misguided 
program in long-term inﬂ ammatory and mental 
activation.
Key messages
• IR is a consequence of mental activation (neuro endo-
crine axes) or inﬂ ammation that is a consequence of 
selﬁ shness of the brain or the immune system.
• IR has been positively selected during evolution for 
short-lived energy-consuming activation of the brain 
or immune system.
• Long-term IR supports mental disease and CIDs 
because energy-rich fuels are provided to these non-
insulin-dependent tissues (continuous activation).
• IR in CIDs is treated by consequent reduction of the 
proinﬂ ammatory load.
• Treatment of IR in morbid obesity and T2D is more 
complex because both inﬂ ammatory and neuro endo-
crine pathways need to be targeted. Th e pleiotropic 
anti-inﬂ ammatory and central nervous eﬀ ects of 
salsalate constitute the ﬁ rst positive drug therapy of IR 
in T2D.
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